The cancer drug developer Novogen has appointed a senior manager of global vaccine maker Sanofi to head the company.
Dr James Garner, who currently leads Sanofi's development unit and is based in Singapore, will begin his new role as Novogen's chief executive officer on February 1.
Novogen said the 42-year-old brings broad experience in drug development and commercialisation, including leading clinical trials, product registration, reimbursement, medical marketing and business development.
His appointment comes five months after the resignation of the group's former boss Dr Graham Kelly, during which time Iain Ross has been acting CEO.
The company earlier said Dr Kelly had resigned to resume work in non-oncology-based research.
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Novogen's interim chairman Ian Phillips said Dr Garner was joining Novogen at an exciting time.
"I am confident as CEO, he will lead us through the next stage of the Company's development and achieve both our short and long term goals."
Novogen is listed on both the Australian share market and Wall Street's Nasdaq index.
